Michael J. Cork

Jul 30, 2024 | ascpt.onlinelibrary.wiley.com | Emma Guttman-Yassky |Michael J. Cork |Margitta Worm |Matthew P. Kosloski

WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC? Interleukin-33 (IL-33), a proinflammatory alarmin cytokine released by damaged epithelial tissue cells, initiates and amplifies both type 1 and type 2 inflammatory cascades. IL-33 has been suggested as having a role in atopic dermatitis (AD), a chronic, relapsing type 2 inflammatory disease of the skin. Itepekimab is a novel human IgG4P monoclonal antibody against IL-33, currently in development for chronic obstructive pulmonary disease (COPD).

Feb 1, 2023 | jamanetwork.com | Amy S. Paller |Jonathan I. Silverberg |Michael J. Cork |Emma Guttman-Yassky

[Skip to Navigation] Table 2.  Efficacy End Points at Week 16 in Patients With Erythrodermic Atopic DermatitisaTable 3.  Overview of Adverse Events in Patients With Erythrodermic Atopic Dermatitis During the Study Treatment Perioda February 1, 2023 JAMA Dermatol.